US 12,357,560 B2
Composition for treating or preventing skin pigmentation
Sayaka Koide, Tokyo (JP); Masaya Takagi, Tokyo (JP); Shoko Yamada, Tokyo (JP); Ritsuro Ideta, Tokyo (JP); and Takashi Satoh, Tokyo (JP)
Assigned to Shiseido Company, Ltd., Tokyo (JP)
Filed by Shiseido Company, Ltd., Tokyo (JP)
Filed on Jul. 24, 2023, as Appl. No. 18/225,377.
Application 18/225,377 is a division of application No. 17/298,440, abandoned, previously published as PCT/JP2019/046903, filed on Nov. 29, 2019.
Claims priority of application No. 2018-226032 (JP), filed on Nov. 30, 2018.
Prior Publication US 2023/0364006 A1, Nov. 16, 2023
Int. Cl. A61K 8/98 (2006.01); A61Q 19/02 (2006.01)
CPC A61K 8/985 (2013.01) [A61Q 19/02 (2013.01)] 4 Claims
 
1. A method for treatment of skin pigmentation of a subject in need thereof, the method comprising:
applying fibroblasts as an active ingredient to a site of skin pigmentation or a surrounding dermal tissue of the subject, wherein:
the fibroblasts are fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation,
the fibroblasts have lower expression of a cell senescence marker than fibroblasts localized at the site of skin pigmentation,
the fibroblasts are derived from a tissue selected from the group consisting of a gluteal region, an abdominal region, a thorax, a femoral region, an upper arm, a dorsal region, a gingiva, an oral mucosa, a scalp, and an auricle rear,
the cell senescence marker is one or more selected from the group consisting of senescent acidic β-galactosidase (SA-βgal), cell cycle check mechanism-associated factor and cell senescence-associated secretory phenotype (SASP) factor, and
the skin pigmentation is caused by activated melanocytes induced by photo damaged-fibroblasts.